STOCKHOLM – May 19, 2022. Umecrine Cognition AB today announces that the company has submitted a clinical trial application (CTA) for a Phase 2 study of golexanolone in patients with primary…
The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general meeting at 10:00 a.m. on Friday 17 June 2022 at Setterwalls Advokatbyrå’s…
STOCKHOLM – March 14, 2022. Umecrine Cognition AB today announces that the company has completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA). Based on a recent interaction…
STOCKHOLM – February 21, 2022. Umecrine Cognition AB today announces that the company will present positive data from a recently concluded nonclinical study at the 11th International Meeting on…
Stockholm, January 10, 2022 – Umecrine Cognition AB today announced nonclinical results showing that its clinical drug candidate golexanolone exerts a normalizing effect on neuroinflammation in the…
STOCKHOLM – Umecrine Cognition AB today announces new scientific results for its drug candidate golexanolone, linking the drug target allopregnanolone to cognitive symptoms in patients with primary biliary cholangitis. The data will be presented at The Liver Meeting Digital ExperienceTM 2021, the premier Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 12-15.
STOCKHOLM – October 18, 2021. Umecrine Cognition AB today announces the establishment of a collaboration with Professor Trevor G Smart and his research group at University College London. The scope of the collaboration will include molecular and behavioral investigations of Umecrine Cognition’s most advanced drug candidate golexanolone.
STOCKHOLM – October 6, 2021. Umecrine Cognition AB, whose novel orally-active GABAA receptor modulating steroid antagonist, golexanolone, is in clinical development for hepatic encephalopathy (HE) and other CNS-related disorders, will present at two upcoming meetings pertaining to the potential benefit of golexanolone for cognitive abnormalities in patients with liver disease.
STOCKHOLM. Umecrine Cognition announced today that CEO Magnus Doverskog will present at Healthcare Innovation Summit on October 7, 2021. Vator Securities Healthcare Innovation Summit is a digital investor event including some of the most innovative and fastest growing companies in the healthcare sector. The event will include focused insights into these healthcare companies, including fire side chats and panel discussions with experts within healthcare and healthcare investments.
STOCKHOLM. Umecrine Cognition AB today announced that the Journal of Hepatology has published safety, pharmacokinetic, and preliminary efficacy results from the pilot Phase 2a study of golexanolone in patients with cirrhosis and covert hepatic encephalopathy (HE). The clinical trial results demonstrate that the company’s candidate drug, golexanolone, improved neuropsychiatric performance at doses which are well tolerated and exhibit excellent pharmacokinetics.